Autologous interleukin-2-secreting neuroblastoma vaccine (IL-2-secreting NB vaccine)

The autologous interleukin-2-secreting neuroblastoma vaccine is a personalized cancer immunotherapy designed for the treatment of high-risk or recurrent neuroblastoma (Source: St. Jude Children's Research Hospital). This therapeutic approach involves harvesting a patient's own neuroblastoma cells and genetically modifying them to secrete the cytokine interleukin-2 (IL-2), a key regulator of the immune response (Source: PubMed PMID 10449310). By re-introducing these modified cells into the patient, the vaccine provides a localized source of IL-2 that bypasses the systemic toxicities associated with high-dose cytokine therapy while stimulating the activation of cytotoxic T-lymphocytes and natural killer (NK) cells (Source: ClinicalTrials.gov NCT00002834). These activated immune cells are then able to recognize and eliminate residual tumor cells by targeting specific neuroblastoma-associated antigens. Clinical trials have evaluated this vaccine as a strategy to enhance the efficacy of standard treatments like anti-GD2 antibodies (Source: NCI). The goal of the vaccine is to overcome the immunosuppressive microenvironment of the tumor and establish long-term immunological memory to prevent disease relapse (Source: Journal of Clinical Oncology). This treatment represents a significant advancement in cellular therapy for pediatric oncology.

Other names

IL-2-transduced autologous neuroblastoma vaccineGenetically modified autologous neuroblastoma vaccineIL2-NB vaccineAD100

The vaccine utilizes autologous neuroblastoma cells genetically engineered to secrete interleukin-2 (IL-2). Upon injection, the localized secretion of IL-2 stimulates the activation and expansion of tumor-specific cytotoxic T-lymphocytes and natural killer (NK) cells, which recognize and destroy residual neuroblastoma cells by targeting tumor-associated antigens (Source: PubMed PMID 9701207; ClinicalTrials.gov NCT00002834).